Aclidinium bromide vs Umeclidinium/Vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline
Aclidinium bromide · Tudorza Pressair
Marketed by Azurity Pharmaceuticals and partners
NCT00363896 · Phase 3 · completed
The trial randomized 843 participants to double-blind aclidinium or placebo, with trough FEV1 at 12 and 28 weeks, an accepted lung-function endpoint for COPD, as its primary outcome. The registry posts no significance test, but the publication of ACCLAIM/COPD I reports trough FEV1 improvements over placebo of 61 mL and 67 mL at 12 and 28 weeks (both p<0.001).
Reported efficacy
Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide (Week 24, morning pre-dose (trough)): Change from baseline in morning pre-dose (trough) FEV1 at Week 24, aclidinium bromide 400 μg vs placebo: LS mean difference 0.134 L (p<0.001); AB 400 μg 0.050 L vs placebo -0.084 L. (met)
Result source: NCT03022097
Umeclidinium/Vilanterol
Marketed by GlaxoSmithKline and partners
NCT01777334 · Phase 3 · completed
The trial randomly assigned 905 participants and used double blinding with tiotropium as an active comparator. Its primary endpoint was the clinical lung-function measure trough FEV1, and the primary comparison significantly favored umeclidinium/vilanterol.
Reported efficacy
Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): UMEC/VI 62.5/25 µg 0.205 Liters (Standard Error 0.0114) vs TIO 18 µg 0.093 Liters (Standard Error 0.0115) (met)
Result source: NCT01777334
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Aclidinium bromide | Umeclidinium/Vilanterol |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | 0.4 vs 0.6−0.1 vs placeboNCT01966107 | —Trial running · NCT06474039 |
| Trough FEV1, change | 0.1 vs -0.1+0.2 vs placeboNCT0302209725 other results
| 0.2 vs 0.1vs TIONCT017773343 other results
|
| SGRQ total, change | -3.6 vs -1.9−1.8 vs placeboNCT015727927 other results
| —Trial running · NCT06474039 |
| TDI focal score | 2.9 vs 2.1+0.8 vs placeboNCT030220975 other results
| —Trial running · NCT06474039 |
Moderate or severe exacerbations, annualised rate
- Aclidinium bromide
- 0.4 vs 0.6−0.1 vs placeboNCT01966107
- Umeclidinium/Vilanterol
- —Trial running · NCT06474039
Trough FEV1, change
- Aclidinium bromide
- 0.1 vs -0.1+0.2 vs placeboNCT03022097
25 other results
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT01001494
- 0.1 vs -0.0 NCT01437397
- 0.1 vs -0.0 NCT01437397
- 0.1 vs -0.1 NCT01462942
- 0.1 vs -0.1 NCT01462942
- 1.2 vs 1.2 NCT00358436
- 1.2 vs 1.2 NCT00358436
- 0.1 vs -0.0 NCT00891462
- 0.1 vs -0.0 NCT01045161
- 0.1 vs -0.0 NCT01001494
- 0.0 vs -0.1 NCT01001494
- 0.1 vs -0.0 NCT00891462
- 0.0 vs -0.0 NCT01045161
- 0.0 vs -0.0 NCT01001494
- 0.1 vs 0.1 NCT02796677
- 0.0 vs -0.1 NCT01572792
- 0.0 vs -0.1 NCT01572792
- 0.1 vs -0.0 NCT00500318
- 0.1 vs -0.0 NCT02153489
- 0.1 vs -0.0 NCT01120093
- 0.1 vs -0.0 NCT01120093
- 0.1 vs -0.0 NCT01120093
- Umeclidinium/Vilanterol
- 0.2 vs 0.1vs TIONCT01777334
3 other results
- 0.1 vs -0.0 NCT01899742
- 0.2 vs 0.2 NCT02487446
- 0.2 vs 0.2 NCT02487446
SGRQ total, change
- Aclidinium bromide
- -3.6 vs -1.9−1.8 vs placeboNCT01572792
7 other results
- -5.5 vs -1.9 NCT01572792
- -8.7 vs -4.7 NCT03022097
- -7.6 vs -4.7 NCT03022097
- -6.6 vs -2.2 NCT01437397
- -5.9 vs -2.2 NCT01437397
- -7.2 vs -6.5 NCT01462942
- -8.3 vs -6.5 NCT01462942
- Umeclidinium/Vilanterol
- —Trial running · NCT06474039
TDI focal score
- Aclidinium bromide
- 2.9 vs 2.1+0.8 vs placeboNCT03022097
5 other results
- 2.6 vs 2.1 NCT03022097
- 2.0 vs 0.6 NCT01437397
- 2.0 vs 0.6 NCT01437397
- 2.5 vs 1.2 NCT01462942
- 2.4 vs 1.2 NCT01462942
- Umeclidinium/Vilanterol
- —Trial running · NCT06474039
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Aclidinium bromide: 7 of 7 rows · Umeclidinium/Vilanterol: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aclidinium bromide Rows use multiple source trials | Umeclidinium/Vilanterol Rows use multiple source trials |
|---|---|---|
| FEV1 AUC 12-24h absolute change · L | 0.032 vs -0.128 placebo L @ 6wk400 µg BIDa,b,c NCT01462929 · Phase 3 · registry result, not featured evidence | 0.2076 vs 0.2025 Umeclidinium/Vilanterol L @ 12wka,b,c NCT02487446 · Phase 3 · registry result, not featured evidence |
| FEV1 AUC(0-24h absolute change · L | 0.065 vs -0.085 placebo L @ 6wk400 µg BIDa,b,c NCT01462929 · Phase 3 · registry result, not featured evidence | 0.2321 vs 0.2436 Umeclidinium/Vilanterol L @ 12wkd,a,b,c NCT02487446 · Phase 3 · registry result, not featured evidence show 1 more dose0.2321 vs 0.2436 Umeclidinium/Vilanterol L @ 12wk NCT02487446 · Phase 3 · registry result, not featured evidence |
| FEV1 AUC0-12h absolute change · L | 0.236 vs 0.015 placebo L @ 2.142857142857143wk400 μg Bide,a,b,f NCT00868231 · Phase 2 · registry result, not featured evidence | 0.2543 vs 0.2848 Umeclidinium/Vilanterol L @ 12wke,a,b,f NCT02487446 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 14.2%200 μg Once-dailyg NCT00363896 · Phase 3 · monotherapy show 34 more results25.7%200 μg once-daily NCT00358436 · Phase 3 · monotherapy 7.1%400 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 7.9%400/12 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 —400 μg Bid NCT01120093 · Phase 2 —200 μg Bid NCT01120093 · Phase 2 —100 μg Bid NCT01120093 · Phase 2 12.6%400µg NCT00891462 · Phase 3 17.8%200µg NCT00891462 · Phase 3 —400 μg NCT01045161 · Phase 3 —400 μg NCT01045161 · Phase 3 —200 μg NCT01045161 · Phase 3 —200 μg to 400 μg NCT01045161 · Phase 3 6.3%400 μg Bid NCT01001494 · Phase 3 8.7%200 μg Bid NCT01001494 · Phase 3 44.3% NCT01966107 · Phase 4 4.4%400 μg NCT02375724 · Phase 4 · registry result, not featured evidence —400 μg bid NCT02153489 · Phase 4 · registry result, not featured evidence —400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 19.5%400/12 μg NCT01572792 · Phase 3 · registry result, not featured evidence 18.3%400/6 μg NCT01572792 · Phase 3 · registry result, not featured evidence 19.5%400/12 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 18.3%400/6 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 8.8%400/12 μg NCT01462942 · Phase 3 · registry result, not featured evidence 10.5%400/6 μg NCT01462942 · Phase 3 · registry result, not featured evidence —400 μg BID NCT01471171 · Phase 3 · registry result, not featured evidence 2.9%400 µg BID NCT01462929 · Phase 3 · registry result, not featured evidence 44.7%400µg NCT01044459 · Phase 3 · registry result, not featured evidence 42.6%200µg NCT01044459 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 5.8% NCT00500318 · Phase 3 · registry result, not featured evidence —400 μg Bid NCT00868231 · Phase 2 · registry result, not featured evidence | 11.7%62.5/25 µgh NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results—62.5/25 µg once daily NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 — NCT02487446 · Phase 3 · registry result, not featured evidence —27.5/12.5 Bid NCT02487498 · Phase 3 · registry result, not featured evidence 6.9%62.5/25 µg NCT01899742 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 3.8%200 μg Once-dailyg NCT00363896 · Phase 3 · monotherapy show 34 more results4.8%200 μg once-daily NCT00358436 · Phase 3 · monotherapy 1.5%400 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 1.1%400/12 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 —400 μg Bid NCT01120093 · Phase 2 —200 μg Bid NCT01120093 · Phase 2 —100 μg Bid NCT01120093 · Phase 2 3.7%400µg NCT00891462 · Phase 3 4.3%200µg NCT00891462 · Phase 3 —400 μg NCT01045161 · Phase 3 —400 μg NCT01045161 · Phase 3 —200 μg NCT01045161 · Phase 3 —200 μg to 400 μg NCT01045161 · Phase 3 1.5%400 μg Bid NCT01001494 · Phase 3 2.9%200 μg Bid NCT01001494 · Phase 3 — NCT01966107 · Phase 4 1.5%400 μg NCT02375724 · Phase 4 · registry result, not featured evidence —400 μg bid NCT02153489 · Phase 4 · registry result, not featured evidence —400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 6.2%400/12 μg NCT01572792 · Phase 3 · registry result, not featured evidence 6.5%400/6 μg NCT01572792 · Phase 3 · registry result, not featured evidence 6.2%400/12 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 6.5%400/6 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 3.1%400/12 μg NCT01462942 · Phase 3 · registry result, not featured evidence 2.6%400/6 μg NCT01462942 · Phase 3 · registry result, not featured evidence —400 μg BID NCT01471171 · Phase 3 · registry result, not featured evidence 1.8%400 µg BID NCT01462929 · Phase 3 · registry result, not featured evidence 6.8%400µg NCT01044459 · Phase 3 · registry result, not featured evidence 7.1%200µg NCT01044459 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 3.5% NCT00500318 · Phase 3 · registry result, not featured evidence —400 μg Bid NCT00868231 · Phase 2 · registry result, not featured evidence | 4%62.5/25 µgh NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results—62.5/25 µg once daily NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 — NCT02487446 · Phase 3 · registry result, not featured evidence —27.5/12.5 Bid NCT02487498 · Phase 3 · registry result, not featured evidence 2%62.5/25 µg NCT01899742 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 8%200 μg Once-dailyg NCT00363896 · Phase 3 · monotherapy show 34 more results10.3%200 μg once-daily NCT00358436 · Phase 3 · monotherapy 7.9%400 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 7.2%400/12 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 1.4%400 μg Bid NCT01120093 · Phase 2 1.4%200 μg Bid NCT01120093 · Phase 2 0%100 μg Bid NCT01120093 · Phase 2 3.2%400µg NCT00891462 · Phase 3 4.3%200µg NCT00891462 · Phase 3 4.5%400 μg NCT01045161 · Phase 3 9.5%400 μg NCT01045161 · Phase 3 6%200 μg NCT01045161 · Phase 3 13%200 μg to 400 μg NCT01045161 · Phase 3 5.6%400 μg Bid NCT01001494 · Phase 3 4.3%200 μg Bid NCT01001494 · Phase 3 22.8% NCT01966107 · Phase 4 1.5%400 μg NCT02375724 · Phase 4 · registry result, not featured evidence 0%400 μg bid NCT02153489 · Phase 4 · registry result, not featured evidence 7.3%400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 7.7%400/12 μg NCT01572792 · Phase 3 · registry result, not featured evidence 6.9%400/6 μg NCT01572792 · Phase 3 · registry result, not featured evidence 5.7%400/12 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 5.4%400/6 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 6%400/12 μg NCT01462942 · Phase 3 · registry result, not featured evidence 4.7%400/6 μg NCT01462942 · Phase 3 · registry result, not featured evidence 0%400 μg BID NCT01471171 · Phase 3 · registry result, not featured evidence 1.8%400 µg BID NCT01462929 · Phase 3 · registry result, not featured evidence 10%400µg NCT01044459 · Phase 3 · registry result, not featured evidence 9.3%200µg NCT01044459 · Phase 3 · registry result, not featured evidence 12.3%400 μg NCT00970268 · Phase 3 · registry result, not featured evidence 15.2%400 μg NCT00970268 · Phase 3 · registry result, not featured evidence 14%200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 15.9%200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 2.3% NCT00500318 · Phase 3 · registry result, not featured evidence 0%400 μg Bid NCT00868231 · Phase 2 · registry result, not featured evidence | 3.5%62.5/25 µgh NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results1.7%62.5/25 µg once daily NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 3.8% NCT02487446 · Phase 3 · registry result, not featured evidence 5%27.5/12.5 Bid NCT02487498 · Phase 3 · registry result, not featured evidence 2.8%62.5/25 µg NCT01899742 · Phase 3 · registry result, not featured evidence 0.5%62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 200 μg Once-dailyg nasopharyngitis 16.3% (placebo 14.4%) headache 11.3% (placebo 12.5%) back pain 4.8% (placebo 4.6%) NCT00363896 · Phase 3 · monotherapy show 34 more results200 μg once-daily headache 14.2% (placebo 12.7%) nasopharyngitis 12.7% (placebo 11.3%) upper respiratory tract infection 10.8% (placebo 9.8%) NCT00358436 · Phase 3 · monotherapy 400 μg upper respiratory tract infection 9.4% (placebo 8.9%) chronic obstructive pulmonary disease 7.9% (placebo 13%) NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 400/12 μg upper respiratory tract infection 11.8% (placebo 8.9%) chronic obstructive pulmonary disease 9.5% (placebo 13%) NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 400 μg copd exacerbation 13% (placebo 11.5%) upper respiratory tract infection 1.7% (placebo 0.5%) nasopharyngitis 1.1% (placebo 0%) NCT01045161 · Phase 3 400 μg copd exacerbation 27.9% (placebo 11.5%) upper respiratory tract infection 5.4% (placebo 0.5%) nasopharyngitis 4.1% (placebo 0%) NCT01045161 · Phase 3 200 μg copd exacerbation 8.7% (placebo 11.5%) upper respiratory tract infection 1.6% (placebo 0.5%) nasopharyngitis 1.1% (placebo 0%) NCT01045161 · Phase 3 200 μg to 400 μg copd exacerbation 22.7% (placebo 11.5%) nasopharyngitis 5.8% (placebo 0%) upper respiratory tract infection 5.8% (placebo 0.5%) NCT01045161 · Phase 3 400 μg Bid chronic obstructivce pulmonary disease 14.1% (placebo 20.5%) headache 12.3% (placebo 8.1%) nasopharyngitis 11.2% (placebo 8.4%) NCT01001494 · Phase 3 200 μg Bid chronic obstructivce pulmonary disease 15.9% (placebo 20.5%) nasopharyngitis 11.6% (placebo 8.4%) headache 10.8% (placebo 8.1%) NCT01001494 · Phase 3 urinary tract infection 5% (placebo 4.7%) upper respiratory tract infection 4.8% (placebo 5.6%) viral upper respiratory tract infection 4.4% (placebo 3.7%) NCT01966107 · Phase 4 400 μg headache 5.2% (placebo 9.7%) nasopharyngitis 3% (placebo 6.7%) NCT02375724 · Phase 4 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary 15.6% nasopharyngitis 11.5% headache 5.1% NCT02796677 · Phase 3 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary disease 20.3% (placebo 15.8%) urinary tract infection 8.2% (placebo 5.5%) nasopharyngitis 7.7% (placebo 4.8%) NCT01572792 · Phase 3 · registry result, not featured evidence 400/6 μg chronic obstructive pulmonary disease 22.1% (placebo 15.8%) nasopharyngitis 6.9% (placebo 4.8%) urinary tract infection 6.4% (placebo 5.5%) NCT01572792 · Phase 3 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary disease 15.2% (placebo 17.5%) cough 5.1% (placebo 3.6%) nasopharyngitis 4.8% (placebo 3.6%) NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 400/6 μg chronic obstructive pulmonary disease 14.7% (placebo 17.5%) nasopharyngitis 5.1% (placebo 3.6%) cough 3.9% (placebo 3.6%) NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 400/12 μg chronic obstructive pulmonary disease 8.6% (placebo 11.9%) nasopharyngitis 7.8% (placebo 7.2%) headache 7.5% (placebo 8.2%) NCT01462942 · Phase 3 · registry result, not featured evidence 400/6 μg chronic obstructive pulmonary disease 9.4% (placebo 11.9%) nasopharyngitis 7.9% (placebo 7.2%) headache 7.1% (placebo 8.2%) NCT01462942 · Phase 3 · registry result, not featured evidence 400 μg BID nasopharyngitis 6.3% (placebo 3.7%) NCT01471171 · Phase 3 · registry result, not featured evidence 400 µg BID nasopharyngitis 6.4% (placebo 2.4%) headache 3.5% (placebo 4.7%) NCT01462929 · Phase 3 · registry result, not featured evidence 400µg chronic obstructive pulmonary disease 19.9% NCT01044459 · Phase 3 · registry result, not featured evidence 200µg chronic obstructive pulmonary disease 19.3% NCT01044459 · Phase 3 · registry result, not featured evidence 400 μg chronic obstructive pulmonary disorder 22.6% nasopharyngitis 9.4% urinary tract infection 7.5% NCT00970268 · Phase 3 · registry result, not featured evidence 400 μg chronic obstructive pulmonary disorder 30.4% contusion 10.9% cough 8.7% NCT00970268 · Phase 3 · registry result, not featured evidence 200 μg chronic obstructive pulmonary disorder 24.7% nasopharyngitis 8.6% back pain 7.5% NCT00970268 · Phase 3 · registry result, not featured evidence 200 μg chronic obstructive pulmonary disorder 36.4% sinusitis 11.4% upper respiratory tract infection 11.4% NCT00970268 · Phase 3 · registry result, not featured evidence cough 5.8% (placebo 3.2%) headache 5.8% (placebo 7.4%) upper respiratory tract infection 5.8% (placebo 2.1%) NCT00500318 · Phase 3 · registry result, not featured evidence 400 μg Bid diarrhoea 6.9% (placebo 0%) chronic obstructive pulmonary disease 0% (placebo 10%) NCT00868231 · Phase 2 · registry result, not featured evidence | 62.5/25 µgh headache 8.8% nasopharyngitis 6.2% cough 2.9% NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results62.5/25 µg once daily nasopharyngitis 4% headache 3.5% NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 chronic obstructive pulmonary disease 10.6% nasopharyngitis 5.6% oropharyngeal pain 2.9% NCT02487446 · Phase 3 · registry result, not featured evidence 27.5/12.5 Bid chronic obstructive pulmonary disease 14.8% bronchitis 3.3% sinusitis 1.8% NCT02487498 · Phase 3 · registry result, not featured evidence 62.5/25 µg nasopharyngitis 7.3% headache 6.5% NCT01899742 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 12 weeks versus 6 weeks.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eTrial phases differ: Phase 3 versus Phase 2.
- fAssessment timepoints differ: 12 weeks versus 2.142857142857143 weeks.
- gPopulation comparability has not been reviewed for 31 of these studies.
- hPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aclidinium bromide
show 1 more result
show 3 more results
show 8 more results
show 8 more results
show 5 more results
show 7 more results
show 3 more results
show 3 more results
show 1 more result
+ 26 further endpoints in the CSV export.
Umeclidinium/Vilanterol
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide's landscape · Umeclidinium/Vilanterol's landscape